315 related articles for article (PubMed ID: 35347591)
1. Integrating Precision Medicine into the Contemporary Management of Gynecologic Cancers.
Wolford JE; Ferrigni E; Margul D; Herzog TJ
Curr Oncol Rep; 2022 Jul; 24(7):889-904. PubMed ID: 35347591
[TBL] [Abstract][Full Text] [Related]
2. Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know.
Liu J; Westin SN
Gynecol Oncol; 2016 Apr; 141(1):65-71. PubMed ID: 27016231
[TBL] [Abstract][Full Text] [Related]
3. Genomic-Based Therapy of Gynecologic Malignancies.
Markman M
Acta Med Acad; 2019 Apr; 48(1):84-89. PubMed ID: 31264436
[TBL] [Abstract][Full Text] [Related]
4. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
5. PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?
Lightfoot M; Montemorano L; Bixel K
Curr Oncol Rep; 2020 Feb; 22(3):29. PubMed ID: 32067102
[TBL] [Abstract][Full Text] [Related]
6. The NCI-MATCH trial and precision medicine in gynecologic cancers.
Barroilhet L; Matulonis U
Gynecol Oncol; 2018 Mar; 148(3):585-590. PubMed ID: 29366510
[TBL] [Abstract][Full Text] [Related]
7. Updates in the Use of Targeted Therapies for Gynecologic Cancers.
Cantillo E; Blanc-Durand F; Leary A; Slomovitz BM; Fuh K; Washington C
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e438582. PubMed ID: 38788185
[TBL] [Abstract][Full Text] [Related]
8. The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers.
Chelariu-Raicu A; Zibetti Dal Molin G; Coleman RL
Int J Gynecol Cancer; 2020 Oct; 30(10):1608-1618. PubMed ID: 32928926
[TBL] [Abstract][Full Text] [Related]
9. An attempt to establish real-world databases of poly(ADP-ribose) polymerase inhibitors for advanced or recurrent epithelial ovarian cancer: the Japanese Gynecologic Oncology Group.
Shimada M; Yoshihara K; Tanigawa T; Nomura H; Hamanishi J; Fujiwara S; Tanabe H; Kajiyama H; Mandai M; Aoki D; Enomoto T; Okamoto A
J Gynecol Oncol; 2023 May; 34(3):e62. PubMed ID: 37116954
[TBL] [Abstract][Full Text] [Related]
10. Novel Therapies in Gynecologic Cancer.
Bejar FG; Oaknin A; Williamson C; Mayadev J; Peters PN; Secord AA; Wield AM; Coffman LG
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-17. PubMed ID: 35594502
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy for gynecologic cancers: Toward the era of precision medicine.
Basu P; Mukhopadhyay A; Konishi I
Int J Gynaecol Obstet; 2018 Oct; 143 Suppl 2():131-136. PubMed ID: 30306576
[TBL] [Abstract][Full Text] [Related]
12. Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer.
Shim SH; Lee JY; Lee YY; Park JY; Lee YJ; Kim SI; Han GH; Yang EJ; Noh JJ; Yim GW; Son JH; Kim NK; Kim TH; Kong TW; Choi YJ; Cho A; Lim H; Jang EB; Cho HW; Suh DH
J Gynecol Oncol; 2024 Mar; 35(2):e66. PubMed ID: 38330382
[TBL] [Abstract][Full Text] [Related]
13. [Place of PARP inhibitors in the treatment of endometrial and cervical cancers].
Le Gac M; Koual M; Delanoy N; Perkins G; Nguyen-Xuan HT; Blons H; Le Frère-Belda MA; Laurent-Puig P; Bentivegna E; Durdux C; Azaïs H; Bats AS
Bull Cancer; 2022 Jan; 109(1):65-75. PubMed ID: 34801228
[TBL] [Abstract][Full Text] [Related]
14. Targeting PARP for the optimal immunotherapy efficiency in gynecologic malignancies.
Li T; Wang X; Qin S; Chen B; Yi M; Zhou J
Biomed Pharmacother; 2023 Jun; 162():114712. PubMed ID: 37075667
[TBL] [Abstract][Full Text] [Related]
15. mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: a critical review.
Husseinzadeh N; Husseinzadeh HD
Gynecol Oncol; 2014 May; 133(2):375-81. PubMed ID: 24556063
[TBL] [Abstract][Full Text] [Related]
16. Current Systemic Treatment Landscape of Advanced Gynecologic Malignancies.
Pan K; Gong J; Huynh K; Cristea M
Target Oncol; 2019 Jun; 14(3):269-283. PubMed ID: 31069647
[TBL] [Abstract][Full Text] [Related]
17. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence.
Wang Q; Peng H; Qi X; Wu M; Zhao X
Signal Transduct Target Ther; 2020 Jul; 5(1):137. PubMed ID: 32728057
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers.
Sa JK; Hwang JR; Cho YJ; Ryu JY; Choi JJ; Jeong SY; Kim J; Kim MS; Paik ES; Lee YY; Choi CH; Kim TJ; Kim BG; Bae DS; Lee Y; Her NG; Shin YJ; Cho HJ; Kim JY; Seo YJ; Koo H; Oh JW; Lee T; Kim HS; Song SY; Bae JS; Park WY; Han HD; Ahn HJ; Sood AK; Rabadan R; Lee JK; Nam DH; Lee JW
Genome Biol; 2019 Nov; 20(1):253. PubMed ID: 31771620
[TBL] [Abstract][Full Text] [Related]
20. Novel frontiers in urogenital cancers: from molecular bases to preclinical models to tailor personalized treatments in ovarian and prostate cancer patients.
De Lazzari G; Opattova A; Arena S
J Exp Clin Cancer Res; 2024 May; 43(1):146. PubMed ID: 38750579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]